Abstracts tagged "Diabetes"

Abstract Number: 3047 • 2016 ACR/ARHP Annual Meeting
Diabetes and BMI Modify the Association Between Painful Hip OA and All-Cause Mortality
Rebecca Cleveland¹, Todd A. Schwartz², Jordan B. Renner³, Leigh F. Callahan¹ and Joanne M. Jordan¹, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Individuals with specific comorbid conditions have increased risk of having hip osteoarthritis (OA). Some of these conditions are also associated with increased risk of…
Abstract Number: 3078 • 2016 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis and Diabetes- Using Genetic Risk Scores to Explore the Association
Melissa Wang¹, Mariko Ishimori², Greg Kinney³, Irina Ianculsecu¹, Elizabeth Regan⁴, Michael Weisman⁵ and Mark Goodarzi⁶, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Medicine, National Jewish Health, Denver, CO, ⁵Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ⁶Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is a poorly understood condition characterized by new bone formation mainly affecting the spine. An association of DISH with…
Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Jeffrey R. Curtis¹, Ara Dikranian², Alan Mendelsohn³, Koshika Soma⁴, Haiyun Fan³ and Chudy Nduaka³, ¹University of Alabama at Birmingham, Birmingham, AL, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting
High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis
Lihi Eder¹, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…
Abstract Number: 331 • 2015 ACR/ARHP Annual Meeting
Are Metabolic Factors Associated with Shoulder Osteoarthritis? a Multicentric Study.
Pierre-Antoine Juge¹, Laure Bérard², Salma Kotti³, Tabassome Simon⁴, Francis Berenbaum⁵, Geoffroy Nourissat⁶ and Jérémie Sellam⁷, ¹Rheumatology Department, Saint-Antoine Hospital, Paris, France, ²Rheumatology Department, Le Havre Hospital, Le Havre, France, ³Unité de Recherche Clinique de l’Est Parisien, Saint-Antoine Hospital, Paris, France, ⁴Unité de Recherche Clinique de l'Est Parisien URCEST, Saint-Antoine Hospital, AP-HP, Univ Paris 06, Paris, France, ⁵Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁶Orthopedic surgery, Clinique des Maussins & St-Antoine Hospital AP-HP, Paris, France, ⁷Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France
Background/Purpose: Aging, trauma and obesity are the 3 main risk factors for knee, hip and hand osteoarthritis (OA). It is noteworthy that risk factors for…
Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, Jonathan Chapnick⁴ and Javier Nuevo⁵, ¹4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
Abstract Number: 2260 • 2015 ACR/ARHP Annual Meeting
High Prevalence of Hypomagnesemia and Its Relation to BMI, Type 2 Diabetes, and Clinical Disease Measures in a VA Outpatient Rheumatology Clinic Population
Nitika Ghattaura¹, Caleb Murphy² and Peter Valen^2,3, ¹Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota Medical School, Minneapolis, MN, ³Rheumatology, Minneapolis VAMC, Minneapolis, MN
Background/Purpose: Magnesium plays an essential role in multiple cellular reactions, and there is increasing interest in its role in inflammation and pain. It has been…
Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Barbara Missler-Karger¹, Hans-Eckhard Langer², Mika Leinonen³ and Björn Pilström⁴, ¹Rheumatology consultant, Cologne, Germany, ²RHIO Research Institute, Düsseldorf, Germany, ³4Pharma AB, Stockholm, Sweden, ⁴TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^2,3,4, Eric C. Sayre³, Michal Abrahamowicz⁵, John M. Esdaile^2,6,7 and Diane Lacaille^8,9,10, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
Abstract Number: 1276 • 2014 ACR/ARHP Annual Meeting
Hyperglycemia and Risk of Osteoarthritis
Mona Walimbe¹, Ann V. Schwartz², Irina Tolstykh², Charles E. McCulloch², David T. Felson³, Cora E. Lewis⁴, Neil A. Segal⁵, Michael C. Nevitt² and Nancy E. Lane⁶, ¹Medicine, UCSF (University of California, San Francisco), San Francisco, CA, ²Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁵Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁶Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA
Background/Purpose Osteoarthritis (OA) is reported to be more prevalent in individuals with diabetes mellitus (DM). Potential etiologies include advanced glycation endproducts, which reduce cartilage integrity,…
Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting
Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase
Pari Basharat¹, Arash Lahouti H.¹, Andrew L. Mammen², Iago Pinal-Fernandez¹, Tanmayee Bichile³, Thomas E. Lloyd⁴, Sonye K. Danoff⁵, Livia Casciola-Rosen⁶ and Lisa Christopher-Stine⁷, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ³Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Neurology, Johns Hopkins, Baltimore, MD, ⁵Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁶Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
Abstract Number: 1113 • 2014 ACR/ARHP Annual Meeting
Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study
Asuncion Acosta Sr.¹, Arturo Rodriguez de la Serna², Berta Magallares² and Gary Sterba Sr.³, ¹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³rheumatology, rheumatologist, miami, FL
Background/Purpose: Painful syndrome of the mayor trochanter(MTPS).The treatment includes intra-bursal injections with corticosteroids.Steroids.Estimate the efficacy of the treatment with hyaluronic acid injections in comparison to…
Abstract Number: 1064 • 2014 ACR/ARHP Annual Meeting
Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control
Ulf Müller-Ladner¹, Stefan Kleinert², Klaus Krüger³, Bianca Wittig⁴ and Rolf Hecker⁴, ¹Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Abt. Rheumatologie und klinische Immunologie, Bad Nauheim, Germany, ²Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ³Praxiszentrum St. Bonifatius, München, Germany, ⁴Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany
Background/Purpose More than 50% of premature deaths in patients with rheumatoid arthritis (RA) are due to cardiovascular disease (CVD). Both the cumulative burden of inflammation…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 514 • 2014 ACR/ARHP Annual Meeting
Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Katja Perdan-Pirkmajer¹, Sergej Pirkmajer², Alojzija Hocevar¹, ŽIga Rotar¹, Natasa Gaspersic¹, Sonja Praprotnik¹, Matija Tomsic³ and Ales Ambrozic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Institute of Pathophysiology, Faculty of Medicine Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].